Other substances

MPI5

A candidate 3C-like protease inhibitor.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

Supporting references

Contradictory references

AI-suggested references

Clinical trials

Structure image - MPI5

CC(C)C(NC(=O)OCC1=CC=CC=C1)C(=O)NC(CC1CCCCC1)C(=O)NC(CC1CCNC1=O)C=O

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
A Quick Route to Multiple Highly Potent SARS‐CoV‐2 Main Protease Inhibitors 3CLpro Small molecule In vitro	X-ray crystallography; Vero E6 cells; A549/ACE2 cells	3.12	Bound the SARS-CoV-2 3C-like protease in vitro and abolished the SARS-CoV-2-induced cytopathic effect in Vero E6 cells and even more (sub-miclomolar) in A549/ACE2 cells, which was hypothesized to be at least in part due to modulation of the host proteases by the compound.	Dec/07/2020

AI-suggested references

Link	Publication date
MPI8 is Potent against SARS-CoV-2 by Inhibiting Dually and Selectively the SARS-CoV-2 Main Protease and the Host Cathepsin L**	Jul/29/2021
A Quick Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors*.	Dec/10/2020
Evaluation of SARS-CoV-2 Main Protease Inhibitors Using a Novel Cell-Based Assay.	Feb/02/2022